Table 2.
Demographics, baseline clinical data, and CT scores at baseline and last CT grouped by osteitis severity at last CT
| No osteitis, | Moderate osteitis, | Severe osteitis, | |
|---|---|---|---|
| n = 45 | n = 34 | n = 37 | |
| Demographic data | |||
| Women; n (%) | 23 (51) | 15 (44) | 15 (41) |
| Limited GPA, as defined in WGET research group; n (%) | 18 (40) | 15 (44) | 19 (51) |
| Mean age at diagnosis in years (SD) | 44 (20) | 54 (18) | 39 (18) |
| Median time in years between symptom onset and diagnosis (range) | 44; 0.4 (0.0–9.3) | 0.7 (0.0–6.0) | 0.4 (0.1–10.0) |
| Missing = 1 | |||
| Median time in years from diagnosis to first CT (range) | 0.1 (−3.9–18.5) | 0.3 (−2.3–16.1) | 0.5 (−1.3–24.6) |
| Median time in years between first and last CT (range) | 4.5 (1.3–12.9) | 4.8 (1.1–13.5) | 7.3 (2.1–14.7) |
| Ever smokers; fraction (%) | 17/36 (47) | 14/30 (47) | 17/28 (61) |
| Mortality; n (%) | 3 (7) | 3 (9) | 4 (11) |
| Laboratory data | |||
| ANCA positive; fraction (%) | 44/45 (98) | 33/33 (100) | 32/32 (100) |
| ANCA negative; fraction (%) | 1/45 (2.2) | 0/33 (0) | 0/32 (0) |
| Baseline clinical data, BVAS | |||
| General; n (%) | 42 (93) | 32 (94) | 33 (89) |
| Cutaneous; n (%) | 11 (24) | 7 (21) | 8 (22) |
| Mucosal membranes/eyes; n (%) | 14 (31) | 10 (29) | 9 (24) |
| Ear, nose, and throat; n (%) | 42 (93) | 29 (85) | 36 (97) |
| Bloody nasal discharge/crusts/ulcers/granulomata; n (%) | 35 (78) | 25 (74) | 33 (89) |
| Paranasal sinus involvement; n (%) | 23 (51) | 23 (68) | 33 (89) |
| Subglottic stenosis; n (%) | 0 (0) | 0 (0) | 0 (0) |
| Conductive hearing loss; n (%) | 15 (33) | 6 (18) | 12 (32) |
| Sensorineural hearing loss; n (%) | 5 (11) | 1 (3) | 1 (3) |
| Chest; n (%) | 26 (58) | 21 (62) | 22 (59) |
| Cardiovascular; n (%) | 1 (2) | 0 (0) | 0 (0) |
| Abdominal; n (%) | 3 (7) | 1 (3) | 2 (5) |
| Renal; n (%) | 27 (60) | 20 (59) | 15 (41) |
| Nervous system; n (%) | 7 (16) | 4 (12) | 10 (27) |
| Surgery at end of follow-up | |||
| Sinus surgery; n (%) | 1 (2) | 4 (12) | 17 (46) |
| CT scores at baseline | |||
| Median GOSS (range) | 0 (0–0) | 2 (0–18) | 6 (0–38) |
| Sinonasal destructions; n (%) | 3 (7) | 6 (18) | 20 (54) |
| Nasal septum perforation; n (%) | 3 (7) | 4 (12) | 5 (14) |
| Saddle nose deformity; n (%) | 2 (4) | 1 (3) | 5 (14) |
| Median LM-score (range) | 1 (0–12) | 4 (0–22) | 9 (0–22) |
| LM-score >0; n (%) | 29 (64) | 30 (88) | 36 (97) |
| CT scores at last CT | |||
| Median GOSS (range) | 0 (0–0) | 4 (1–28) | 16 (5–49) |
| Sinonasal destructions; n (%) | 6 (13) | 11 (32) | 33 (89) |
| Nasal septum perforation; n (%) | 6 (13) | 7 (21) | 13 (35) |
| Saddle nose deformity; n (%) | 2 (4) | 4 (12) | 10 (27) |
| Median LM-score (range) | 1 (0–7) | 4 (0–20) | 7 (0–22) |
Missing data on ANCA and smoking
Abbreviations:GPA granulomatosis with polyangiitis, WGET Wegener’s Granulomatosis Etanercept Trial, ANCA anti-neutrophil cytoplasmic antibodies, BVAS Birmingham Vasculitis Activity Score, version 3, GOSS Global Osteitis Scoring Scale, LM-score Lund-Mackay score